Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment
In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively ana...
Saved in:
Published in | BMC neurology Vol. 22; no. 1; pp. 1 - 9 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BioMed Central Ltd
20.09.2022
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively analyze the levels of different plasma factors, IL-6, MMP-9, ADAMTS13, TNC, GSN and TRX, using Luminex assays or ELISA measurements. Compared with the levels assessed at the onset of AIS, the levels of MMP-9 (
P
< 0.001), ADAMTS13 (
P
< 0.001), and TRX (
P
< 0.001) significantly decreased after IVT. The level of IL-6 was significantly increased in the NIHSS > 5 group at admission (
P
< 0.001) compared to the NIHSS ≤ 5 group. AIS patients with a poor prognosis had lower levels of ADAMTS13 at 72 h post-IVT compared with patients with a good prognosis (
P
= 0.021). IL-6 also was notably higher in the poor outcome group (
P
= 0.012). After adjusting for confounders, ADAMTS13 at 72 h post-IVT was an independent protective factor for prognosis in AIS patients with an adjusted OR of 0.07 (
P
= 0.049), whereas IL-6 was an independent predictor of risk for AIS patients with an adjusted OR of 1.152 (
P
= 0.028). IVT decreased MMP-9, ADAMTS13, and TRX levels in the plasma of AIS patients. Patients with a NIHSS score of less than 5 exhibited lower IL-6 levels, indicating that increased levels of IL-6 correlated with AIS severity after IVT. Therefore, IL-6 and ADAMTS13 might be useful plasma markers to predict the prognosis in AIS patients at 90-days after IVT. |
---|---|
AbstractList | In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively analyze the levels of different plasma factors, IL-6, MMP-9, ADAMTS13, TNC, GSN and TRX, using Luminex assays or ELISA measurements. Compared with the levels assessed at the onset of AIS, the levels of MMP-9 (P < 0.001), ADAMTS13 (P < 0.001), and TRX (P < 0.001) significantly decreased after IVT. The level of IL-6 was significantly increased in the NIHSS > 5 group at admission (P < 0.001) compared to the NIHSS ≤ 5 group. AIS patients with a poor prognosis had lower levels of ADAMTS13 at 72 h post-IVT compared with patients with a good prognosis (P = 0.021). IL-6 also was notably higher in the poor outcome group (P = 0.012). After adjusting for confounders, ADAMTS13 at 72 h post-IVT was an independent protective factor for prognosis in AIS patients with an adjusted OR of 0.07 (P = 0.049), whereas IL-6 was an independent predictor of risk for AIS patients with an adjusted OR of 1.152 (P = 0.028). IVT decreased MMP-9, ADAMTS13, and TRX levels in the plasma of AIS patients. Patients with a NIHSS score of less than 5 exhibited lower IL-6 levels, indicating that increased levels of IL-6 correlated with AIS severity after IVT. Therefore, IL-6 and ADAMTS13 might be useful plasma markers to predict the prognosis in AIS patients at 90-days after IVT.In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively analyze the levels of different plasma factors, IL-6, MMP-9, ADAMTS13, TNC, GSN and TRX, using Luminex assays or ELISA measurements. Compared with the levels assessed at the onset of AIS, the levels of MMP-9 (P < 0.001), ADAMTS13 (P < 0.001), and TRX (P < 0.001) significantly decreased after IVT. The level of IL-6 was significantly increased in the NIHSS > 5 group at admission (P < 0.001) compared to the NIHSS ≤ 5 group. AIS patients with a poor prognosis had lower levels of ADAMTS13 at 72 h post-IVT compared with patients with a good prognosis (P = 0.021). IL-6 also was notably higher in the poor outcome group (P = 0.012). After adjusting for confounders, ADAMTS13 at 72 h post-IVT was an independent protective factor for prognosis in AIS patients with an adjusted OR of 0.07 (P = 0.049), whereas IL-6 was an independent predictor of risk for AIS patients with an adjusted OR of 1.152 (P = 0.028). IVT decreased MMP-9, ADAMTS13, and TRX levels in the plasma of AIS patients. Patients with a NIHSS score of less than 5 exhibited lower IL-6 levels, indicating that increased levels of IL-6 correlated with AIS severity after IVT. Therefore, IL-6 and ADAMTS13 might be useful plasma markers to predict the prognosis in AIS patients at 90-days after IVT. Abstract In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively analyze the levels of different plasma factors, IL-6, MMP-9, ADAMTS13, TNC, GSN and TRX, using Luminex assays or ELISA measurements. Compared with the levels assessed at the onset of AIS, the levels of MMP-9 (P < 0.001), ADAMTS13 (P < 0.001), and TRX (P < 0.001) significantly decreased after IVT. The level of IL-6 was significantly increased in the NIHSS > 5 group at admission (P < 0.001) compared to the NIHSS ≤ 5 group. AIS patients with a poor prognosis had lower levels of ADAMTS13 at 72 h post-IVT compared with patients with a good prognosis (P = 0.021). IL-6 also was notably higher in the poor outcome group (P = 0.012). After adjusting for confounders, ADAMTS13 at 72 h post-IVT was an independent protective factor for prognosis in AIS patients with an adjusted OR of 0.07 (P = 0.049), whereas IL-6 was an independent predictor of risk for AIS patients with an adjusted OR of 1.152 (P = 0.028). IVT decreased MMP-9, ADAMTS13, and TRX levels in the plasma of AIS patients. Patients with a NIHSS score of less than 5 exhibited lower IL-6 levels, indicating that increased levels of IL-6 correlated with AIS severity after IVT. Therefore, IL-6 and ADAMTS13 might be useful plasma markers to predict the prognosis in AIS patients at 90-days after IVT. In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively analyze the levels of different plasma factors, IL-6, MMP-9, ADAMTS13, TNC, GSN and TRX, using Luminex assays or ELISA measurements. Compared with the levels assessed at the onset of AIS, the levels of MMP-9 (P < 0.001), ADAMTS13 (P < 0.001), and TRX (P < 0.001) significantly decreased after IVT. The level of IL-6 was significantly increased in the NIHSS > 5 group at admission (P < 0.001) compared to the NIHSS ≤ 5 group. AIS patients with a poor prognosis had lower levels of ADAMTS13 at 72 h post-IVT compared with patients with a good prognosis (P = 0.021). IL-6 also was notably higher in the poor outcome group (P = 0.012). After adjusting for confounders, ADAMTS13 at 72 h post-IVT was an independent protective factor for prognosis in AIS patients with an adjusted OR of 0.07 (P = 0.049), whereas IL-6 was an independent predictor of risk for AIS patients with an adjusted OR of 1.152 (P = 0.028). IVT decreased MMP-9, ADAMTS13, and TRX levels in the plasma of AIS patients. Patients with a NIHSS score of less than 5 exhibited lower IL-6 levels, indicating that increased levels of IL-6 correlated with AIS severity after IVT. Therefore, IL-6 and ADAMTS13 might be useful plasma markers to predict the prognosis in AIS patients at 90-days after IVT. In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively analyze the levels of different plasma factors, IL-6, MMP-9, ADAMTS13, TNC, GSN and TRX, using Luminex assays or ELISA measurements. Compared with the levels assessed at the onset of AIS, the levels of MMP-9 ( P < 0.001), ADAMTS13 ( P < 0.001), and TRX ( P < 0.001) significantly decreased after IVT. The level of IL-6 was significantly increased in the NIHSS > 5 group at admission ( P < 0.001) compared to the NIHSS ≤ 5 group. AIS patients with a poor prognosis had lower levels of ADAMTS13 at 72 h post-IVT compared with patients with a good prognosis ( P = 0.021). IL-6 also was notably higher in the poor outcome group ( P = 0.012). After adjusting for confounders, ADAMTS13 at 72 h post-IVT was an independent protective factor for prognosis in AIS patients with an adjusted OR of 0.07 ( P = 0.049), whereas IL-6 was an independent predictor of risk for AIS patients with an adjusted OR of 1.152 ( P = 0.028). IVT decreased MMP-9, ADAMTS13, and TRX levels in the plasma of AIS patients. Patients with a NIHSS score of less than 5 exhibited lower IL-6 levels, indicating that increased levels of IL-6 correlated with AIS severity after IVT. Therefore, IL-6 and ADAMTS13 might be useful plasma markers to predict the prognosis in AIS patients at 90-days after IVT. In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively analyze the levels of different plasma factors, IL-6, MMP-9, ADAMTS13, TNC, GSN and TRX, using Luminex assays or ELISA measurements. Compared with the levels assessed at the onset of AIS, the levels of MMP-9 (P < 0.001), ADAMTS13 (P < 0.001), and TRX (P < 0.001) significantly decreased after IVT. The level of IL-6 was significantly increased in the NIHSS > 5 group at admission (P < 0.001) compared to the NIHSS [less than or equai to] 5 group. AIS patients with a poor prognosis had lower levels of ADAMTS13 at 72 h post-IVT compared with patients with a good prognosis (P = 0.021). IL-6 also was notably higher in the poor outcome group (P = 0.012). After adjusting for confounders, ADAMTS13 at 72 h post-IVT was an independent protective factor for prognosis in AIS patients with an adjusted OR of 0.07 (P = 0.049), whereas IL-6 was an independent predictor of risk for AIS patients with an adjusted OR of 1.152 (P = 0.028). IVT decreased MMP-9, ADAMTS13, and TRX levels in the plasma of AIS patients. Patients with a NIHSS score of less than 5 exhibited lower IL-6 levels, indicating that increased levels of IL-6 correlated with AIS severity after IVT. Therefore, IL-6 and ADAMTS13 might be useful plasma markers to predict the prognosis in AIS patients at 90-days after IVT. In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively analyze the levels of different plasma factors, IL-6, MMP-9, ADAMTS13, TNC, GSN and TRX, using Luminex assays or ELISA measurements. Compared with the levels assessed at the onset of AIS, the levels of MMP-9 (P < 0.001), ADAMTS13 (P < 0.001), and TRX (P < 0.001) significantly decreased after IVT. The level of IL-6 was significantly increased in the NIHSS > 5 group at admission (P < 0.001) compared to the NIHSS [less than or equai to] 5 group. AIS patients with a poor prognosis had lower levels of ADAMTS13 at 72 h post-IVT compared with patients with a good prognosis (P = 0.021). IL-6 also was notably higher in the poor outcome group (P = 0.012). After adjusting for confounders, ADAMTS13 at 72 h post-IVT was an independent protective factor for prognosis in AIS patients with an adjusted OR of 0.07 (P = 0.049), whereas IL-6 was an independent predictor of risk for AIS patients with an adjusted OR of 1.152 (P = 0.028). IVT decreased MMP-9, ADAMTS13, and TRX levels in the plasma of AIS patients. Patients with a NIHSS score of less than 5 exhibited lower IL-6 levels, indicating that increased levels of IL-6 correlated with AIS severity after IVT. Therefore, IL-6 and ADAMTS13 might be useful plasma markers to predict the prognosis in AIS patients at 90-days after IVT. Keywords: Acute ischemic stroke, Intravenous thrombolysis, Plasma factors, NIHSS score, Prognosis |
ArticleNumber | 359 |
Audience | Academic |
Author | Zhong, Xin Jiao, Xue Jiang, Bingjian Gao, Zhili Li, Siyi Liu, Yuping Chen, Zhi Lu, Huanhuan Lin, Yushen He, Guoyong Wei, Jinhong Huang, Shuxuan Li, Yanhua |
Author_xml | – sequence: 1 givenname: Huanhuan surname: Lu fullname: Lu, Huanhuan – sequence: 2 givenname: Siyi surname: Li fullname: Li, Siyi – sequence: 3 givenname: Xin surname: Zhong fullname: Zhong, Xin – sequence: 4 givenname: Shuxuan surname: Huang fullname: Huang, Shuxuan – sequence: 5 givenname: Xue surname: Jiao fullname: Jiao, Xue – sequence: 6 givenname: Guoyong surname: He fullname: He, Guoyong – sequence: 7 givenname: Bingjian surname: Jiang fullname: Jiang, Bingjian – sequence: 8 givenname: Yuping surname: Liu fullname: Liu, Yuping – sequence: 9 givenname: Zhili surname: Gao fullname: Gao, Zhili – sequence: 10 givenname: Jinhong surname: Wei fullname: Wei, Jinhong – sequence: 11 givenname: Yushen surname: Lin fullname: Lin, Yushen – sequence: 12 givenname: Zhi surname: Chen fullname: Chen, Zhi – sequence: 13 givenname: Yanhua surname: Li fullname: Li, Yanhua |
BookMark | eNp9ks1u1DAUhSNUJNrCC7CyxIZNiu04trNBqip-RqrEBtaW49zMeEjiYDuDuu-Dc9MpgqkQiqJE9jlfco_PRXE2hQmK4jWjV4xp-S4xrnVVUs7x1o0u5bPinAnFSl4pdfbX-4viIqU9pUxpwc6L-804QudtBhKW7MIIZI5hO4WUvSMHOyy40ZN5sGm0pLcuh5iIn8hss4cpJ_LT5x2xbkGCT24HI_pSjuE7ENtniCjO0R5gCksieRfD2IbhbqXnCDaPCHlZPO_tkODV4_Oy-Pbxw9ebz-Xtl0-bm-vb0tWC5pJrwYFJxaBytJcAjZNQs5ratrGi0rrrtGaaVq1zWtra1a7ljZR1p3pZU11dFpsjtwt2b-boRxvvTLDePCyEuDU24p8NYNquEcBaTRshBFe8lbxyGqhVXMm-A2S9P7LmpcUEHaxTDifQ053J78w2HEwjtGJcIuDtIyCGHwukbEbMD4bBToBRGa6YrHktqgalb55I92GJE0aFKi6pbqRmf1RbiwP4qQ_4XbdCzbXCkghO2cq6-ocKr249OWxV73H9xKCPBhdDShF643zGww_rWH4wjJq1guZYQYMVNA8VNOuI_In1dzz_Mf0CYGPiqQ |
CitedBy_id | crossref_primary_10_1186_s41983_024_00829_5 crossref_primary_10_4103_jcsr_jcsr_251_22 crossref_primary_10_3390_biom15040470 |
Cites_doi | 10.31083/j.jin2003078 10.1097/CRD.0000000000000021 10.1182/bloodadvances.2019000979 10.1016/j.neuroscience.2020.10.034 10.14336/AD.2018.0820 10.1136/neurintsurg-2021-018589 10.1007/s11011-019-00403-6 10.1038/jcbfm.2012.88 10.1007/s00018-019-03175-5 10.1111/ane.13487 10.1212/WNL.0000000000005162 10.1016/j.jstrokecerebrovasdis.2009.10.008 10.3389/fneur.2021.744909 10.1016/j.jstrokecerebrovasdis.2016.09.043 10.12659/MSM.908441 10.1212/WNL.0000000000011268 10.1186/1742-2094-5-45 10.1111/ene.14199 10.1038/nri1664 10.1186/1471-2377-11-41 10.1177/0271678X211056392 10.1371/journal.pmed.1000145 10.1186/1471-2377-4-2 10.1089/ars.2012.4757 10.1016/S1474-4422(21)00252-0 10.1016/S1474-4422(21)00237-4 10.1186/s12883-019-1375-6 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2022 BioMed Central Ltd. 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022. The Author(s). The Author(s) 2022 |
Copyright_xml | – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022. The Author(s). – notice: The Author(s) 2022 |
DBID | AAYXX CITATION 3V. 7TK 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s12883-022-02898-6 |
DatabaseName | CrossRef ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1471-2377 |
EndPage | 9 |
ExternalDocumentID | oai_doaj_org_article_bd94e1b809444272b623c8e0a7276fde PMC9487126 A718642019 10_1186_s12883_022_02898_6 |
GeographicLocations | Taiwan China |
GeographicLocations_xml | – name: Taiwan – name: China |
GrantInformation_xml | – fundername: ; grantid: 82160239 – fundername: ; grantid: 2020GXNSFAA297002 – fundername: ; grantid: S2019089 |
GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABIVO ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IGS IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB PMFND 3V. 7TK 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c540t-2842e1671e3c0f6ee9c6e5150ab9a4388dd881803bcc86a5c5cb29665d7f65083 |
IEDL.DBID | M48 |
ISSN | 1471-2377 |
IngestDate | Wed Aug 27 01:30:46 EDT 2025 Thu Aug 21 18:39:53 EDT 2025 Fri Jul 11 07:23:03 EDT 2025 Fri Jul 25 21:41:25 EDT 2025 Tue Jun 17 21:01:15 EDT 2025 Tue Jun 10 20:41:23 EDT 2025 Tue Jul 01 00:37:38 EDT 2025 Thu Apr 24 22:56:26 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c540t-2842e1671e3c0f6ee9c6e5150ab9a4388dd881803bcc86a5c5cb29665d7f65083 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://www.proquest.com/docview/2726089681?pq-origsite=%requestingapplication% |
PQID | 2726089681 |
PQPubID | 44772 |
PageCount | 9 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_bd94e1b809444272b623c8e0a7276fde pubmedcentral_primary_oai_pubmedcentral_nih_gov_9487126 proquest_miscellaneous_2716525439 proquest_journals_2726089681 gale_infotracmisc_A718642019 gale_infotracacademiconefile_A718642019 crossref_citationtrail_10_1186_s12883_022_02898_6 crossref_primary_10_1186_s12883_022_02898_6 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-09-20 |
PublicationDateYYYYMMDD | 2022-09-20 |
PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-20 day: 20 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London |
PublicationTitle | BMC neurology |
PublicationYear | 2022 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | H Tang (2898_CR9) 2021; 12 CJ Smith (2898_CR14) 2004; 4 B Chelluboina (2898_CR27) 2022; 42 J Montaner (2898_CR7) 2019; 76 M Ramos-Fernandez (2898_CR22) 2011; 20 MK McCoy (2898_CR13) 2008; 5 V Prochazka (2898_CR25) 2018; 24 A Jurcau (2898_CR3) 2021; 20 W Whiteley (2898_CR11) 2009; 6 G Tsivgoulis (2898_CR8) 2020; 27 SM Allan (2898_CR12) 2005; 5 GBD 2019 Stroke collaborators (2898_CR1) 2021; 20 L Mechtouff (2898_CR5) 2021; 96 G Turc (2898_CR2) 2022; 14 MM Abdelnaseer (2898_CR21) 2017; 26 A Bustamante (2898_CR24) 2018; 90 DF Mahmood (2898_CR26) 2013; 19 E Reiche (2898_CR17) 2019; 34 F Purroy (2898_CR16) 2021; 144 A Taylor (2898_CR23) 2020; 4 DS Reich (2898_CR4) 2021; 20 J Hartman (2898_CR20) 2014; 22 KL Lambertsen (2898_CR10) 2012; 32 A Mengel (2898_CR19) 2019; 19 X Li (2898_CR18) 2019; 10 AS Douglas (2898_CR6) 2021; 453 M Beridze (2898_CR15) 2011; 11 |
References_xml | – volume: 20 start-page: 727 year: 2021 ident: 2898_CR3 publication-title: J Integr Neurosci doi: 10.31083/j.jin2003078 – volume: 22 start-page: 147 year: 2014 ident: 2898_CR20 publication-title: Cardiol Rev doi: 10.1097/CRD.0000000000000021 – volume: 4 start-page: 398 year: 2020 ident: 2898_CR23 publication-title: Blood Adv doi: 10.1182/bloodadvances.2019000979 – volume: 453 start-page: 256 year: 2021 ident: 2898_CR6 publication-title: Neurosci doi: 10.1016/j.neuroscience.2020.10.034 – volume: 10 start-page: 544 year: 2019 ident: 2898_CR18 publication-title: Aging Dis doi: 10.14336/AD.2018.0820 – volume: 14 start-page: 209 year: 2022 ident: 2898_CR2 publication-title: J Neurointerv Surg doi: 10.1136/neurintsurg-2021-018589 – volume: 34 start-page: 789 year: 2019 ident: 2898_CR17 publication-title: Metab Brain Dis doi: 10.1007/s11011-019-00403-6 – volume: 32 start-page: 1677 year: 2012 ident: 2898_CR10 publication-title: J Cereb Blood Flow Metab doi: 10.1038/jcbfm.2012.88 – volume: 76 start-page: 3117 year: 2019 ident: 2898_CR7 publication-title: Cell Mol Life Sci doi: 10.1007/s00018-019-03175-5 – volume: 144 start-page: 517 year: 2021 ident: 2898_CR16 publication-title: Acta Neurol Scand doi: 10.1111/ane.13487 – volume: 90 start-page: e995 year: 2018 ident: 2898_CR24 publication-title: Neurol doi: 10.1212/WNL.0000000000005162 – volume: 20 start-page: 47 year: 2011 ident: 2898_CR22 publication-title: J Stroke Cerebrovasc Dis doi: 10.1016/j.jstrokecerebrovasdis.2009.10.008 – volume: 12 start-page: 744909 year: 2021 ident: 2898_CR9 publication-title: Front Neurol doi: 10.3389/fneur.2021.744909 – volume: 26 start-page: 733 year: 2017 ident: 2898_CR21 publication-title: J Stroke Cerebrovasc Dis doi: 10.1016/j.jstrokecerebrovasdis.2016.09.043 – volume: 24 start-page: 3929 year: 2018 ident: 2898_CR25 publication-title: Med Sci Monit doi: 10.12659/MSM.908441 – volume: 96 start-page: e752 year: 2021 ident: 2898_CR5 publication-title: Neurol doi: 10.1212/WNL.0000000000011268 – volume: 5 start-page: 45 year: 2008 ident: 2898_CR13 publication-title: J Neuroinflammation doi: 10.1186/1742-2094-5-45 – volume: 27 start-page: 1039 year: 2020 ident: 2898_CR8 publication-title: Eur J Neurol doi: 10.1111/ene.14199 – volume: 5 start-page: 629 year: 2005 ident: 2898_CR12 publication-title: Nat Rev Immunol doi: 10.1038/nri1664 – volume: 11 start-page: 41 year: 2011 ident: 2898_CR15 publication-title: BMC Neurol doi: 10.1186/1471-2377-11-41 – volume: 42 start-page: 253 year: 2022 ident: 2898_CR27 publication-title: J Cereb Blood Flow Metab doi: 10.1177/0271678X211056392 – volume: 6 start-page: e1000145 year: 2009 ident: 2898_CR11 publication-title: PLOS MED doi: 10.1371/journal.pmed.1000145 – volume: 4 start-page: 2 year: 2004 ident: 2898_CR14 publication-title: BMC Neurol doi: 10.1186/1471-2377-4-2 – volume: 19 start-page: 1266 year: 2013 ident: 2898_CR26 publication-title: Antioxid Redox Signal doi: 10.1089/ars.2012.4757 – volume: 20 start-page: 795 year: 2021 ident: 2898_CR1 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(21)00252-0 – volume: 20 start-page: 729 year: 2021 ident: 2898_CR4 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(21)00237-4 – volume: 19 start-page: 148 year: 2019 ident: 2898_CR19 publication-title: BMC Neurol doi: 10.1186/s12883-019-1375-6 |
SSID | ssj0017841 |
Score | 2.3224258 |
Snippet | In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with... Abstract In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT... |
SourceID | doaj pubmedcentral proquest gale crossref |
SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
StartPage | 1 |
SubjectTerms | Acute ischemic stroke Analysis Biomarkers Blood pressure Cardiac arrhythmia Cardiovascular disease Diabetes Enzyme-linked immunosorbent assay Gelatinase B Hemorrhage Hyperlipidemia Hypertension Interleukin 6 Intravenous administration Intravenous therapy Intravenous thrombolysis Ischemia NIHSS score Normal distribution Patient outcomes Patients Plasma Plasma cells Plasma factors Prevention Prognosis Risk factors Statistical analysis Stroke Stroke (Disease) Thrombolysis Thrombolytic drugs Tumors |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Nb9UwDI_QDogL4lMUBgoSEgdUrUnbNDluE9NAGicm7RblwxVP7LXTXt-BO384dpr3tIIEF66NkzaxE9uN_TNj7xrQMnbal73pTdkEdFC0in0pa-MiOGGioUThiy_q_LL5fNVe3Sn1RTFhMzzwvHBHPpoGhNfohjSN7KRHfR00VA4Vr-oj0OmLOm_nTOX7A7pN26XIaHW0EVRUt6TIdbpZ06VaqKGE1v_nmfx7nOQdxXP2iD3MFiM_nr_0MbsHwxN2_yLfiT9lPz-tU_rHBHzcTihAwCnoahgJgZkTmDc29PwGzeS147m-Dl8NPEOqbjj9i-UubHGEFTq7FC7PN9Pt-B14KiGOxBNVKSI0V051FdZ-vP5Bo-_D1J-xy7OPX0_Py1xboQxoo00laiUJQnUC6lD1CsAEBWjbVM4b19Rax6gpDbz2IWjl2tAGL9E1amPXk1FXP2cHwzjAC8Y1jqNFMEpTQoNXnqwkU7kQ2t7FVhZM7Jbahgw8TvUvrm1yQLSyM3sssscm9lhVsA_7Pjcz7MZfqU-Ig3tKgsxOD1CQbBYk-y9BKth74r-ljY2fF1zOT8BJEkSWPUYtjs4amsQFO1xQ4oYMy-adBNl8IGwsvlBVGtdIFOztvpl6UpDbAMhApBGqJXACHKJbSN5iZsuWYfUtgYIb9DyFVC__x1K8Yg9k2isGD9FDdjDdbuE12l6Tf5O22S_eSi3h priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZokVAvCAqogYJcqRIHZHWdh2OfUEFUBak9UWlvll-BVbvJsskeuPPDmfF6AwGp17XjrDMz9jf2zDeEnJZB5r6WljWqUax04KBI4RuWF8r4YLjyChOFr67F5U35ZV7N04Fbn8Iqd2tiXKh95_CM_CyvAXlLJSR_v_rBsGoU3q6mEhp75CFSl6FW1_PR4eJ4p7ZLlJHirOdYWpdh_Drer0kmJptR5Oz_f2X-N1ryr-3n4gl5nHAjPd8K-il5ENpD8ugq3Yw_I78-L2MSyBBotxlgSoFi6FXbIQ8zRUpvaGjoCsDy0tBUZYcuWpqIVXuKJ7LUuA2MsACXF4PmaT-su9tAYyFx6DxgrSLkdKVYXWFpu7ufOPoYrP6c3Fx8-vrxkqUKC8wBUhsY7E154KLmoXCzRoSgnAiAcGbGKlMWUnovMRm8sM5JYSpXOZuDg1T5ukFoV7wg-23XhiNCJYwjuQMBYVqDFRaxkpoZ56rG-CrPCN99au0S_ThWwbjT0Q2RQm_Fo0E8OopHi4y8G59Zbck37u39ASU49kTi7PhDt_6mkx1q61UZuJXg1ZYl6JQF-OdkmBnAcaLxISNvUf4azRv-njMpSwEmiURZ-hz2cnDZABhn5HjSE8zSTZt3GqTTstDrP0qckZOxGZ_EULc2gAChDxcVUhTAEPVE8yYzm7a0i--RGlyB_8lz8fL-l78iB3m0AgWL5DHZH9ab8Bqw1WDfRAP6Db6HJbM priority: 102 providerName: ProQuest |
Title | Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment |
URI | https://www.proquest.com/docview/2726089681 https://www.proquest.com/docview/2716525439 https://pubmed.ncbi.nlm.nih.gov/PMC9487126 https://doaj.org/article/bd94e1b809444272b623c8e0a7276fde |
Volume | 22 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEA_3AeKL-InVc4kg-CDVph_5eBC5lTtOYQ85XFh8CUma6uJue-52wXv3D3cm265WD8GXPjTptM3MdGaamd8Q8iz3Mi2FtHGlKhXnDgIUycsqTjNlSm-YKhUWCk_O-dk0fz8rZnukb3fULeD62tAO-0lNV4uX379dvQGFfx0UXvJXa4Ytc2PMS8d9MxnzfXIIlklgR4NJ_mtXAffYQrWRYPAwQvRFNNfSGBiqgOf_91f7z0zK30zT6W1yq_Mp6fFWCO6QPV_fJTcm3a75PfLj3TIUiLSeNpsWRMxTTMuqG8Ropgj3DQMVvQRHemlo14GHzmvaga6uKf6tpcZtgMIc1gwT6um6XTVfPQ1NxmFyi32MEO-VYueFpW0WV0h9l8h-n0xPTz6-PYu77guxAy-ujcFupZ5xwXzmkop7rxz34P0kxiqTZ1KWpcRC8cw6J7kpXOFsCsFTUYoK3b7sATmom9o_JFQCHcmc4hJLHiy36EepxDhXVKYs0oiwfqm166DJsUPGQocQRXK9ZY8G9ujAHs0j8mJ3zeUWmOOfs8fIwd1MBNUOJ5rVZ93pqLalyj2zEiLePE9FasE1dNInBnw8XpU-Is-R_xqFER7Pma6CAV4SQbT0Mdh5COfAaY7I0WAmqKwbDvcSpHuJ13BDnkhYIxaRp7thvBLT4GoPDIQ5jBcIXwAkxEDyBm82HKnnXwJsuILYlKX80X8t3GNyMw1KoeB7ekQO2tXGPwE3rLUjsi9mYkQOxyfnHy5G4WfGKOgbHC_Gn34Cq40zFA |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYBLxVMNLWAkEAcUNc7DsQ8IlUe1S7s9tdLejF-BFd1k2c0K9c7v4Tcyk00CAam3XuOJk3jGM9_E8yDkRepF7HJhwkIWMkwtOCiCuyKME6md10w6iYnCk1M-Ok8_TbPpFvnV5cJgWGWnExtF7SqL_8gP4hyQt5BcsLeL7yF2jcLT1a6FxkYsjv3lD3DZVm_GH4C_L-P46OPZ-1HYdhUILaCTOgR9HHvGc-YTGxXce2m5B6seaSN1mgjhnMAE6MRYK7jObGZNDE5B5vIC4UwC894gN8HwRujs5dPewWN4htcl5gh-sGLYyjfEeHk8zxMhHxi_pkfA_5bg3-jMv8zd0V2y0-JUergRrHtky5f3ya1JexL_gPwcz5ukk9rTal3DEnqKoV5lhXWfKZYQh4GCLgCczzVtu_rQWUnbQq4rin-AqbZrmGEGLjYG6dNVvay-edo0LgfiGnsjYQ1Zit0c5qa6uMTZ--D4h-T8Wtb-Edkuq9LvEipgHsEsCASmURhuEJvJSFubFdplcUBYt9TKtuXOsevGhWrcHsHVhj0K2KMa9igekNf9PYtNsY8rqd8hB3tKLNTdXKiWX1S775VxMvXMCPCi0xRk2ADctMJHGnAjL5wPyCvkv0J1Aq9ndZsVAR-JhbnUIWAHcBEBiAdkf0AJasAOhzsJUq0aWqk_myYgz_thvBND60oPDAQaxjMsiQBT5APJG3zZcKScfW1KkUvwd1nMH1_98Gfk9uhscqJOxqfHe-RO3OwICQp6n2zXy7V_AriuNk-bzUTJ5-vevb8BiMphsg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immediate+outcome+prognostic+value+of+plasma+factors+in+patients+with+acute+ischemic+stroke+after+intravenous+thrombolytic+treatment&rft.jtitle=BMC+neurology&rft.au=Lu%2C+Huanhuan&rft.au=Li%2C+Siyi&rft.au=Zhong%2C+Xin&rft.au=Huang%2C+Shuxuan&rft.date=2022-09-20&rft.issn=1471-2377&rft.eissn=1471-2377&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs12883-022-02898-6&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12883_022_02898_6 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2377&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2377&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2377&client=summon |